Gefitinib News and Research RSS Feed - Gefitinib News and Research

Gefitinib is approved by the Food and Drug Administration (FDA) to treat locally advanced or metastatic non-small cell lung cancer (NSCLC) that has not gotten better after treatment with other chemotherapy. It is available only as part of a special program called the Iressa Access Program. Gefitinib is also being studied in the treatment of other types of cancer.

Gefitinib is an anilinoquinazoline with antineoplastic activity. Gefitinib inhibits the catalytic activity of numerous tyrosine kinases including the epidermal growth factor receptor (EGFR), which may result in inhibition of tyrosine kinase-dependent tumor growth. Specifically, this agent competes with the binding of ATP to the tyrosine kinase domain of EGFR, thereby inhibiting receptor autophosphorylation and resulting in inhibition of signal transduction. Gefitinib may also induce cell cycle arrest and inhibit angiogenesis.
QIAGEN's therascreen EGFR RGQ PCR Kit to guide use of IRESSA for in NSCLC treatment

QIAGEN's therascreen EGFR RGQ PCR Kit to guide use of IRESSA for in NSCLC treatment

QIAGEN N.V. today received U.S. marketing (PMA) approval of its therascreen EGFR RGQ PCR Kit (therascreen EGFR test) as a companion diagnostic to guide the use of AstraZeneca's IRESSA (gefitinib) in the treatment of patients with advanced or metastatic non-small cell lung cancer (NSCLC). [More]
Alabama scientists show how phytochemical in magnolia works against head and neck cancers

Alabama scientists show how phytochemical in magnolia works against head and neck cancers

Magnolias are prized for their large, colorful, fragrant flowers. Does the attractive, showy tree also harbor a potent cancer fighter? [More]
AstraZeneca announces efficacy and safety data for AZD9291 in first-line treatment of EGFRm advanced NSCLC

AstraZeneca announces efficacy and safety data for AZD9291 in first-line treatment of EGFRm advanced NSCLC

AstraZeneca today announced preliminary efficacy and safety data for AZD9291 in the first-line treatment of epidermal growth factor receptor mutation positive (EGFRm) advanced non-small cell lung cancer (NSCLC). [More]
Researchers identify promising combination strategy for treating glioblastomas

Researchers identify promising combination strategy for treating glioblastomas

Therapies that specifically target mutations in a person's cancer have been much-heralded in recent years, yet cancer cells often find a way around them. To address this, researchers at University of California, San Diego School of Medicine and Moores Cancer Center identified a promising combinatorial approach to treating glioblastomas, the most common form of primary brain cancer. [More]
Plasma EGFR mutation cfDNA predicts advanced lung cancer outcome

Plasma EGFR mutation cfDNA predicts advanced lung cancer outcome

Monitoring plasma cell-free DNA levels of epidermal growth factor receptor mutations may indicate prognosis for patients with lung adenocarcinoma after EGFR–tyrosine kinase inhibitor therapy, research suggests. [More]

Rare, complex EGFR mutations adversely affect EGFR–TKI treatment outcomes

Individuals with advanced non-small-cell lung cancer who have rare or complex epidermal growth factor receptor mutations have inferior outcomes in response to EGFR–tyrosine kinase inhibitor treatment compared with those with common mutations, research indicates. [More]
EGFR mutations, ALK translocations not mutually exclusive in NSCLC

EGFR mutations, ALK translocations not mutually exclusive in NSCLC

Researchers from the Republic of Korea have found that epidermal growth factor receptor mutations and anaplastic lymphoma kinase translocations can occur concomitantly in a proportion of patients with non-small-cell lung cancer. [More]
QIAGEN's circulating tumor DNA test CE-IVD marked to assess genomic mutation NSCLC patients

QIAGEN's circulating tumor DNA test CE-IVD marked to assess genomic mutation NSCLC patients

QIAGEN announced today the CE-IVD marking of its novel liquid biopsy-based companion diagnostic that analyzes circulating nucleic acids obtained from blood samples to assess an important genomic mutation in patients with non-small cell lung cancer (NSCLC), the most common form of this cancer. [More]
Postoperative recurrent disease affects NSCLC survival after gefitinib

Postoperative recurrent disease affects NSCLC survival after gefitinib

Patients with postoperative recurrent non-small-cell lung cancer harbouring epidermal growth factor receptor mutations have longer progression-free and overall survival with gefitinib treatment, than those with stage IV disease, Japanese researchers report. [More]
Postoperative recurrent disease affects NSCLC survival after gefitinib

Postoperative recurrent disease affects NSCLC survival after gefitinib

Patients with postoperative recurrent non-small-cell lung cancer harbouring epidermal growth factor receptor mutations have longer progression-free and overall survival with gefitinib treatment, than those with stage IV disease, Japanese researchers report. [More]
First-line dacomitinib may improve advanced NSCLC survival

First-line dacomitinib may improve advanced NSCLC survival

Preliminary research suggests that the second-generation tyrosine kinase inhibitor dacomitinib may improve progression-free survival in patients with advanced non-small-cell lung cancer with epidermal growth factor receptor mutations. [More]
PD-1, PD-L1 differentially expressed in NSCLC

PD-1, PD-L1 differentially expressed in NSCLC

The expression of the immune checkpoint protein programmed death-1 receptor and its ligand varies according to tumour and patient characteristics in oncogene-addicted non-small-cell lung cancer, research indicates. [More]
Commonly used osteoporosis medications may also prevent lung, breast and colon cancers

Commonly used osteoporosis medications may also prevent lung, breast and colon cancers

The most commonly used medications for osteoporosis worldwide, bisphosphonates, may also prevent certain kinds of lung, breast and colon cancers, according to two studies led by researchers at the Icahn School of Medicine at Mount Sinai and published today in the Proceedings of the National Academy of Sciences. [More]
FDA-approved therapy could be effective in older, African American patients with lung cancer

FDA-approved therapy could be effective in older, African American patients with lung cancer

University of Cincinnati researchers have found in a phase-2 clinical trial that a Food and Drug Administration-approved therapy could be effective in treating both older and African American patients with advanced lung cancer who may not be candidates for chemotherapy. [More]
New drug shows promise against treatment-resistant non-small cell lung cancer

New drug shows promise against treatment-resistant non-small cell lung cancer

A new drug that targets not only common cancer-causing genetic mutations in patients with non-small cell lung cancer (NSCLC), but also a form of the mutation that causes resistance to treatment, has shown promising results in patients in a phase I/II clinical trial. [More]

No survival benefit with dacomitinib in pretreated patients with advanced NSCLC

The irreversible, pan-epidermal growth factor receptor tyrosine kinase inhibitor dacomitinib does not offer a survival benefit in pretreated patients with advanced or metastatic non-small-cell lung cancer, phase III trial results show. [More]
Gefitinib drug boosts oesophageal cancer patients' survival by up to six months

Gefitinib drug boosts oesophageal cancer patients' survival by up to six months

Patients with a specific type of oesophageal cancer survived longer when they were given the latest lung cancer drug, according to trial results being presented at the National Cancer Research Institute (NCRI) Cancer Conference today (Wednesday). [More]
EGFR–TKIs linked to reduced chemotherapy sensitivity in NSCLC

EGFR–TKIs linked to reduced chemotherapy sensitivity in NSCLC

Epidermal growth factor receptor–tyrosine kinase inhibitors appear to significantly reduce the efficacy of subsequent chemotherapy in patients with EGFR-mutated non-small-cell lung cancer, Chinese researchers report. [More]
Afatinib active against NSCLC nervous system metastases

Afatinib active against NSCLC nervous system metastases

Heavily pretreated patients with epidermal growth factor receptor-mutated non-small-cell lung cancer and central nervous system metastases may benefit from treatment with afatinib, say German researchers. [More]
VAL-083 drug compound shows promise against non-small cell lung cancer

VAL-083 drug compound shows promise against non-small cell lung cancer

DelMar Pharmaceuticals, Inc., a clinical-stage oncology company, today announced the presentation of promising new data supporting the activity of its lead drug compound, VAL-083, in the treatment of non-small cell lung cancer (NSCLC) at the AACR's New Horizons in Cancer Research: Harnessing Breakthroughs – Targeting Cures. The conference takes place October 9th to 12th in Pudong, Shanghai. [More]
Advertisement
Advertisement